New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
3.92
0.31
+8.59%
Follow PASG
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 0.00% in Q3 FY26, the highest of these four quarters.
ROEROIC
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | −113.8% | −128.9% | −169.1% | −212.3% |
| ROIC | 0.0% | 0.0% | 0.0% | 0.0% |
Debt
Net debt is 4.08× a year’s EBITDA. Debt is 0.00× equity.
Debt / equityNet debt / EBITDA
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.0× | 0.0× | 0.0× | 0.0× |
| Net debt / EBITDA | 3.4× | 4.1× | 2.9× | 4.1× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(113.78%) | (128.90%) | (169.09%) | (212.27%) | |
| (55.28%) | (61.53%) | (69.20%) | (69.68%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(158.14%) | (243.65%) | (810.41%) | (66,164.00%) | |
Free Cash Flow per Share |
(9.56) | (9.37) | (10.43) | (10.14) | |
Free Cash Flow |
(30.34) | (30.04) | (33.48) | (32.62) | |
Capital Expenditures |
1.17 | 0.61 | 0.02 | 0.02 | |
| Other line items | |||||
Cash ROIC |
(46.63%) | (66.63%) | (117.02%) | (161.42%) | |
Operating CF/Net income |
0.69 | 0.81 | 0.93 | 0.99 | |
Depreciation/Fixed assets |
0.21 | 0.79 | — | — | |
Capex/Depreciation |
1.37 | 0.92 | 0.04 | 0.07 | |
Operating CF per Share |
(9.93) | (9.56) | (10.44) | (10.14) | |
Capex per Share |
0.37 | 0.19 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated Nov 12, 2026